353 related articles for article (PubMed ID: 26378048)
1. Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage.
Marzec KA; Lin MZ; Martin JL; Baxter RC
Oncotarget; 2015 Sep; 6(29):26583-98. PubMed ID: 26378048
[TBL] [Abstract][Full Text] [Related]
2. The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.
Lin MZ; Marzec KA; Martin JL; Baxter RC
Oncogene; 2014 Jan; 33(1):85-96. PubMed ID: 23178489
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a role in the anti-tumorigenic effects of 5-Aza-2'-deoxycytidine (AZA) in breast cancer cells.
Zeng L; Jarrett C; Brown K; Gillespie KM; Holly JM; Perks CM
Exp Cell Res; 2013 Aug; 319(14):2282-95. PubMed ID: 23810988
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells.
Butt AJ; Firth SM; King MA; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39174-81. PubMed ID: 10998426
[TBL] [Abstract][Full Text] [Related]
5. Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells.
Sheikh MS; Shao ZM; Hussain A; Clemmons DR; Chen JC; Roberts CT; LeRoith D; Fontana JA
J Cell Physiol; 1993 Jun; 155(3):556-67. PubMed ID: 7684042
[TBL] [Abstract][Full Text] [Related]
6. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
7. Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth.
Pon CK; Firth SM; Baxter RC
Mol Cell Endocrinol; 2015 Jan; 399():354-61. PubMed ID: 25449421
[TBL] [Abstract][Full Text] [Related]
8. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
Amemiya Y; Yang W; Benatar T; Nofech-Mozes S; Yee A; Kahn H; Holloway C; Seth A
Breast Cancer Res Treat; 2011 Apr; 126(2):373-84. PubMed ID: 20464481
[TBL] [Abstract][Full Text] [Related]
9. Undecylprodigiosin selectively induces apoptosis in human breast carcinoma cells independent of p53.
Ho TF; Ma CJ; Lu CH; Tsai YT; Wei YH; Chang JS; Lai JK; Cheuh PJ; Yeh CT; Tang PC; Tsai Chang J; Ko JL; Liu FS; Yen HE; Chang CC
Toxicol Appl Pharmacol; 2007 Dec; 225(3):318-28. PubMed ID: 17881028
[TBL] [Abstract][Full Text] [Related]
10. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
Niu J; Xu Z; Li XN; Han Z
Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
12. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia.
Grimberg A; Coleman CM; Burns TF; Himelstein BP; Koch CJ; Cohen P; El-Deiry WS
J Clin Endocrinol Metab; 2005 Jun; 90(6):3568-74. PubMed ID: 15769996
[TBL] [Abstract][Full Text] [Related]
13. High dose of pyridoxine induces IGFBP-3 mRNA expression in MCF-7 cells and its induction is inhibited by the p53-specific inhibitor pifithrin-α.
Nakari M; Kanouchi H; Oka T
J Nutr Sci Vitaminol (Tokyo); 2011; 57(4):280-4. PubMed ID: 22041910
[TBL] [Abstract][Full Text] [Related]
14. IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T.
Frommer KW; Reichenmiller K; Schutt BS; Hoeflich A; Ranke MB; Dodt G; Elmlinger MW
J Mol Endocrinol; 2006 Aug; 37(1):13-23. PubMed ID: 16901920
[TBL] [Abstract][Full Text] [Related]
15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
16. Growth suppression and cell death by pyridoxal is dependent on p53 in the human breast cancer cell line MCF-7.
Minamino M; Oka T; Kanouchi H
Biosci Biotechnol Biochem; 2015; 79(1):124-9. PubMed ID: 25603814
[TBL] [Abstract][Full Text] [Related]
17. IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer.
de Silva HC; Lin MZ; Phillips L; Martin JL; Baxter RC
Cell Mol Life Sci; 2019 May; 76(10):2015-2030. PubMed ID: 30725116
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Liu W; Zhang R
Int J Oncol; 1998 Apr; 12(4):793-804. PubMed ID: 9499438
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells.
Schedlich LJ; O'Han MK; Leong GM; Baxter RC
Biochem Biophys Res Commun; 2004 Jan; 314(1):83-8. PubMed ID: 14715249
[TBL] [Abstract][Full Text] [Related]
20. Effect of wild-type and mutant E-cadherin on cell proliferation and responsiveness to the chemotherapeutic agents cisplatin, etoposide, and 5-fluorouracil.
Fricke E; Hermannstädter C; Keller G; Fuchs M; Brunner I; Busch R; Höfler H; Becker KF; Luber B
Oncology; 2004; 66(2):150-9. PubMed ID: 15138368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
